Fabiana I. A. L. Layng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fabiana I. A. L. Layng has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Darren Finlay
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, USA
2 shared publications - Kristiina Vuori
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, USA
2 shared publications - Petrus Rudolf de Jong
Sanford Burnham Prebys Medical Discovery Institute
2 shared publications - Animesh Ray
Keck Graduate Institute
1 shared publication Aniruddha J. Deshpande
NCI-designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
1 shared publication- Anupama Sahoo
School of Life Sciences and Immune Synapse Research Center, Gwangju Institute of Science and Technology (GIST), 1 Oryong-dong, Puk-ku, Gwangju 500-712, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 10 December 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 298 (1) , 101477
Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells
- 10 December 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 298 (1) , 101477
Open AccessDiscovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells
- 2 September 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (2) , 385-394
MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAFV600E-Driven Melanoma Growth In Vivo and BRAF/MEK Inhibitor Resistance
- 2 September 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (2) , 385-394
MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAFV600E-Driven Melanoma Growth In Vivo and BRAF/MEK Inhibitor Resistance
- Open Access
- 15 November 2019
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 79 (22) , 5839-5848
Absence of HIF1A Leads to Glycogen Accumulation and an Inflammatory Response That Enables Pancreatic Tumor Growth
Cancer cells respond to hypoxia by upregulating the hypoxia-inducible factor 1α (HIF1A) transcription factor, which drives survival mechanisms that include metabolic adaptation and induction of angiogenesis by VEGF. Pancreatic tumors are poorly vascularized and severely hypoxic. To study the angiogenic role of HIF1A, and specifically probe whether tumors are able to use alternative pathways in its absence, we created a xenograft mouse tumor model of pancreatic cancer lacking HIF1A. After an initial delay of about 30 days, the HIF1A-deficient tumors grew as rapidly as the wild-type tumors and had similar vascularization. These changes were maintained in subsequent passages of tumor xenografts in vivo and in cell lines ex vivo. There were many cancer cells with a "clear-cell" phenotype in the HIF1A-deficient tumors; this was the result of accumulation of glycogen. Single-cell RNA sequencing (scRNA-seq) of the tumors identified hypoxic cancer cells with inhibited glycogen breakdown, which promoted glycogen accumulation and the secretion of inflammatory cytokines, including interleukins 1β (IL1B) and 8 (IL8). scRNA-seq of the mouse tumor stroma showed enrichment of two subsets of myeloid dendritic cells (cDC), cDC1 and cDC2, that secreted proangiogenic cytokines. These results suggest that glycogen accumulation associated with a clear-cell phenotype in hypoxic cancer cells lacking HIF1A can initiate an alternate pathway of cytokine and DC-driven angiogenesis. Inhibiting glycogen accumulation may provide a treatment for cancers with the clear-cell phenotype. Significance: These findings establish a novel mechanism by which tumors support angiogenesis in an HIF1α-independent manner.
- 15 November 2019
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 79 (22) , 5839-5848
Open AccessAbsence of HIF1A Leads to Glycogen Accumulation and an Inflammatory Response That Enables Pancreatic Tumor Growth
Cancer cells respond to hypoxia by upregulating the hypoxia-inducible factor 1α (HIF1A) transcription factor, which drives survival mechanisms that include metabolic adaptation and induction of angiogenesis by VEGF. Pancreatic tumors are poorly vascularized and severely hypoxic. To study the angiogenic role of HIF1A, and specifically probe whether tumors are able to use alternative pathways in its absence, we created a xenograft mouse tumor model of pancreatic cancer lacking HIF1A. After an initial delay of about 30 days, the HIF1A-deficient tumors grew as rapidly as the wild-type tumors and had similar vascularization. These changes were maintained in subsequent passages of tumor xenografts in vivo and in cell lines ex vivo. There were many cancer cells with a "clear-cell" phenotype in the HIF1A-deficient tumors; this was the result of accumulation of glycogen. Single-cell RNA sequencing (scRNA-seq) of the tumors identified hypoxic cancer cells with inhibited glycogen breakdown, which promoted glycogen accumulation and the secretion of inflammatory cytokines, including interleukins 1β (IL1B) and 8 (IL8). scRNA-seq of the mouse tumor stroma showed enrichment of two subsets of myeloid dendritic cells (cDC), cDC1 and cDC2, that secreted proangiogenic cytokines. These results suggest that glycogen accumulation associated with a clear-cell phenotype in hypoxic cancer cells lacking HIF1A can initiate an alternate pathway of cytokine and DC-driven angiogenesis. Inhibiting glycogen accumulation may provide a treatment for cancers with the clear-cell phenotype. Significance: These findings establish a novel mechanism by which tumors support angiogenesis in an HIF1α-independent manner.